Literature DB >> 11028473

Elevated homocysteine levels are associated with increased ischemic myocardial injury in acute coronary syndromes.

M K Al-Obaidi1, P J Stubbs, P Collinson, R Conroy, I Graham, M I Noble.   

Abstract

OBJECTIVES: This study was conducted to determine whether the amount of myocardial damage during acute coronary syndromes (ACS) is related to the admission plasma homocysteine concentration.
BACKGROUND: Elevated homocysteine levels are associated with increased thrombosis in patients presenting with ACS. It is not known whether this association is reflected in the degree of myocardial injury in those patients.
METHODS: We studied consecutive patients presenting with acute myocardial infarction (MI) (n = 205) and unstable angina pectoris (UAP) (n = 185). Plasma samples were collected on admission and prior to clinical intervention and were assayed for homocysteine by high performance liquid chromatography (HPLC). Myocardial necrosis was assessed by measurements of cardiac troponin T (cTnT) on admission and 12 h after admission (peak cTnT). The patients were studied by quintiles of homocysteine concentration.
RESULTS: There was a significant increase in peak cTnT in the 5th homocysteine quintile in MI (analysis of variance [ANOVA], p = 0.005), the levels being 4.10, 3.86, 4.13, 6.20 and 7.85 microg/liter for quintiles 1 to 5, respectively (p < 0.0001, for top vs. bottom quintile). Similarly, there was a step-up in peak cTnT levels in the top homocysteine quintile in UAP (ANOVA, p < 0.0001), the levels being 0.03, 0.03, 0.02, 0.04 and 0.15 microg/liter, (p < 0.0001 for top vs. bottom quintile). In a multivariate regression model, the association between peak cTnT and the top homocysteine quintile remained strong after adjustment of other confounders including age, gender, final diagnosis and thrombolysis treatment (odds ratio [OR]: 2.92 (1.75-4.87) p < 0.0001). The patients with UAP were further examined according to peak cTnT levels below (cTnT negative) or above (cTnT positive) 0.1 microg/liter. Homocysteine levels were significantly higher in cTnT positive than cTnT negative patients; 13.8 (11.7-15.3) vs. 10.3 (9.4-11.3) micromol/liter, respectively, p = 0.002.
CONCLUSIONS: Elevated homocysteine levels are associated with a higher risk of ischemic myocardial injury in patients presenting with ACS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11028473     DOI: 10.1016/s0735-1097(00)00820-2

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  5 in total

1.  The relationship between the concentration of plasma homocysteine and chronic kidney disease: a cross sectional study of a large cohort.

Authors:  Eytan Cohen; Ili Margalit; Tzippy Shochat; Elad Goldberg; Ilan Krause
Journal:  J Nephrol       Date:  2019-06-05       Impact factor: 3.902

2.  Changes in serum homocysteine level follow two different trends in patients during early post myocardial infarction period.

Authors:  Amina Valjevac; Alen Dzubur; Emina Nakas-Ićindić; Almira Hadzović-Dzuvo; Asija Zaćiragić; Orhan Lepara; Amila Arslanagić
Journal:  Bosn J Basic Med Sci       Date:  2009-05       Impact factor: 3.363

3.  Hyperhomocysteinemia in a young woman presenting with acute myocardial infarction: Case report.

Authors:  Seher Gokay; Davran Ciçek; Haldun Müderrisoğlu
Journal:  Interv Med Appl Sci       Date:  2013-03-19

4.  Metabolic Disorders and Anesthesia.

Authors:  Cindy Yeoh; Howard Teng; Jacob Jackson; Lee Hingula; Takeshi Irie; Aron Legler; Corrine Levine; Iris Chu; Casey Chai; Luis Tollinche
Journal:  Curr Anesthesiol Rep       Date:  2019-07-12

5.  The serum anion gap is associated with disease severity and all-cause mortality in coronary artery disease.

Authors:  Shi-Wei Yang; Yu-Jie Zhou; Ying-Xin Zhao; Yu-Yang Liu; Xiao-Fang Tian; Zhi-Jian Wang; De-An Jia; Hong-Ya Han; Bin Hu; Hua Shen; Fei Gao; Lu-Ya Wang; Jie Lin; Guo-Zhong Pan; Jian Zhang; Zhen-Feng Guo; Jie Du; Da-Yi Hu
Journal:  J Geriatr Cardiol       Date:  2017-06       Impact factor: 3.327

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.